On first glance they beat guidance which was $1.25m NPAT, but around $300k of reported NPAT is due to a release of provisions. Still, it is very cheap.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025